Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Floorless Preferred Stock/Debenture -- Ignore unavailable to you. Want to Upgrade?

To: Zeev Hed who wrote (989)	9/30/1999 8:04:00 PM
From: OpusX	Read Replies (1) \| Respond to of 1438

Zeev, I feel stupid, I had the MOA backward. Ranolazine partially shifts the hearts metabolism of fatty acids to glucose metabolism. Since it's easier to metabolize glucose (less ATP per unit of energy) the heart's workload is lessened. All curent therapies for angina either decrease Heart rate and or blood pressure. Ranolazine does not affect these parameters. This is a big plus since these patients are usually on other med's that also decrease HR &/or BP. The result is the heart works more efficiently and deteriorates less over time. 1/3 of est. 7.2 MM US patients are inadequately treated for angina. 48.8% inst. ownership Sorry I spaced on the MOA I wanted to post right away, so I didn't lead people astray :^) More DD coming (gee this is fun) Robert